
    
      This is a single-centre, double-blinded, randomised controlled trial of palifermin
      (Kepivance) vs. placebo in the prevention of autoimmunity following alemtuzumab treatment of
      multiple sclerosis.

      The dose of palifermin (kepivance)used in this trial will be informed by a dose-escalation
      study.
    
  